TrialInternational journal of hematology2026

Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial.

Kenshi Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.